Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study-Reference-Cited by-同舟云学术

Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study

Published:2023-12-28 Issue:26 Volume:142 Page:2327-2331
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Qualls David A.¹^ORCID,Lambert Nicholas²,Caimi Paolo F.³^ORCID,Merrill Mwanasha⁴^ORCID,Pullarkat Priyanka⁵,Godby Richard C.⁶,Bond David A.⁷^ORCID,Wehmeyer Graham T.⁸^ORCID,Romancik Jason⁹^ORCID,Amoozgar Behzad¹⁰,Leslie Lori¹¹,Nastoupil Loretta J.¹²^ORCID,Crombie Jennifer L.⁴^ORCID,Abramson Jeremy S.⁵^ORCID,Khurana Arushi⁶,Nowakowski Grzegorz S.⁶,Maddocks Kami⁷,Rutherford Sarah C.⁸,Kahl Brad¹⁰,Okwali Michelle¹,Buege Michael J.¹^ORCID,Seshan Venkatraman¹^ORCID,Batlevi Connie L.¹^ORCID,Salles Gilles¹¹³^ORCID

Affiliation:

1. 1Lymphoma Service, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY

2. 2Department of Medicine, Baylor College of Medicine, Houston, TX

3. 3Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH

4. 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

5. 5Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA

6. 6Hematology Division, Department of Internal Medicine, Mayo Clinic, Rochester, MN

7. 7Division of Hematology, The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH

8. 8Department of Medicine, Meyer Cancer Center, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY

9. 9Department of Hematology and Medical Oncology, Winship Cancer Institute at Emory University, Atlanta, GA

10. 10Department of Medicine, Washington University School of Medicine, St Louis, MO

11. 11Lymphoma Division, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ

12. 12Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

13. 13Weill Cornell Medical College, New York, NY

Abstract

Abstract In this real-world evaluation of tafasitamab-lenalidomide (TL) in relapsed or refractory LBCL, patients receiving TL had higher rates of comorbidities and high-risk disease characteristics, and substantially lower progression-free survival and overall survival, compared with the L-MIND registration clinical trial for TL.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

https://ashpublications.org/blood/article-pdf/142/26/2327/2178057/blood_bld-2023-021274-main.pdf

Reference12 articles.

1. US Food and Drug Administration . FDA grants accelerated approval to tafasitamab-cxix for diffuse large B-cell lymphoma. Last updated 3 August 2020. Accessed 3 February 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-accelerated-approval-tafasitamab-cxix-diffuse-large-b-cell-lymphoma.

2. The European Medicines Agency review of tafasitamab in combination with lenalidomide for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma;Delgado;Hemasphere,2021

3. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study;Salles;Lancet Oncol,2020

4. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma;Duell;Haematologica,2021

5. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy;Cheson;Blood,2016

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phage display for discovery of anticancer antibodies;New Biotechnology;2024-11

2. The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas;Blood Advances;2024-09-10

3. Eligibility for clinical trials in diffuse large B-cell lymphoma: are we sweating the small stuff?;Leukemia & Lymphoma;2024-09-05

4. Utilization of Real-World Data to Facilitate Clinical Trials for Patients with Lymphoma;Pharmacoepidemiology;2024-08-06

5. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20